RxDoctor Payments Data

Eric Harris, DO

Medical Oncology · Daytona Beach, FLNPI 1902068158

Payments from drug & device makers

$1,171,763in general payments, 2019–2025

Across 1,007 payments — averaging $1163.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$442K
  • Mirati Therapeutics, Inc.$186K
  • Taiho Oncology, Inc.$115K
  • Immunomedics, Inc.$83K
  • Bristol Myers Squibb$63K
  • Beigene, Ltd.$63K
  • plus $219K from 54 others

What the payments were for

  • Consulting fees$12,90313%
  • Speaking & faculty fees$63,47165%
  • Travel & lodging$5,2655%
  • Food & beverage$13,54314%
  • Education$2560%
  • Other$1,5312%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)71$441,887
Mirati Therapeutics, Inc.43$186,046
Taiho Oncology, Inc.60$114,700
Immunomedics, Inc.10$82,916
Bristol Myers Squibb46$63,199
Beigene, Ltd.27$63,183
Novartis120$50,252
Gilead(2 entities)62$40,866
E.r. Squibb & Sons, L.L.C.58$33,732
Eli Lilly2$23,241
Takeda Pharmaceuticals U.S.A., Inc.16$22,192
Genentech, Inc.8$20,270
Merck41$9,111
Amgen(2 entities)16$5,436
Astrazeneca UK Limited3$4,856
Seagen Inc.18$1,202
Rigel Pharmaceuticals, Inc.2$1,014
Johnson & Johnson(2 entities)38$642
Pfizer35$636
Genentech USA, Inc.31$456
Bayer14$320
AbbVie11$314
Daiichi Sankyo Inc.16$298
Incyte Corporation16$293
Lilly USA, LLC17$285
Sanofi15$271
Eisai Inc.12$256
Exelixis Inc.13$247
GSK10$225
Regeneron Healthcare Solutions, Inc.10$221
Astellas Pharma US Inc13$209
Pharmacosmos Therapeutics Inc.8$188
Tersera Therapeutics LLC7$186
Ipsen Biopharmaceuticals, Inc11$170
EMD Serono, Inc.8$160
Beigene USA, Inc.9$143
Jazz Pharmaceuticals Inc.8$143
Array Biopharma Inc9$136
Boehringer Ingelheim6$122
Sobi, Inc5$117
Foundation Medicine, Inc.3$113
Galvanize Therapeutics, Inc1$103
Puma Biotechnology, Inc.6$101
Dendreon Pharmaceuticals LLC3$79
Sanofi-aventis U.S. LLC4$77
Tesaro, Inc.3$72
Geron Corporation3$60
Beone Medicines USA, Inc.2$59
Lexicon Pharmaceuticals, Inc.3$58
Heron Therapeutics, Inc.2$57
Pharmaessentia USA Corporation3$57
Stemline Therapeutics Inc.2$54
AVEO Pharmaceuticals, Inc.2$52
G1 Therapeutics, Inc.3$52
Agios Pharmaceuticals, Inc.3$48
Secura Bio, Inc.4$43
AMAG Pharmaceuticals, Inc.3$41
CSL Behring2$39
Legend Biotech USA Inc.2$36
Clovis Oncology, Inc.3$36

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,171,763 in reported general payments places this provider in the 80th percentile of 507 medical oncology providers in Florida.

See all medical oncology providers in Florida

Medicare billing

Part B allowed, 2024
$3,691,294
Medicare patients
529
Services billed
142,778

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide47$712,933
TasignaNilotinib Hcl18$363,591
CabometyxCabozantinib S-Malate12$300,877
PomalystPomalidomide12$257,845
XtandiEnzalutamide17$238,573
Lenalidomide14$222,840
CalquenceAcalabrutinib Maleate15$203,873
BrukinsaZanubrutinib15$172,100
KisqaliRibociclib Succinate12$159,182
VenclextaVenetoclax12$115,062
EliquisApixaban51$41,741
Abiraterone Acetate17$28,481
XareltoRivaroxaban24$15,830
Anastrozole199$4,843
Exemestane20$3,464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$63,199$712,93347 claims
NovartisTasigna, Kisqali$50,252$522,77330 claims
Exelixis Inc.Cabometyx$247$300,87712 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$33,732$257,84512 claims
Astellas Pharma US IncXtandi$209$238,57317 claims
AstraZenecaCalquence$441,887$203,87315 claims
Beigene USA, Inc.Brukinsa$143$172,10015 claims
AbbVieVenclexta$314$115,06212 claims
PfizerEliquis$636$41,74151 claims
Johnson & JohnsonXarelto$642$15,83024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 507 medical oncology providers in Florida.

Other medical oncology in Daytona Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →